Purpose: To assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of cetrelimab (JNJ-63723283), a monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced/refractory solid tumors in the phase 1/2 LUC1001 study.
Methods: In phase 1, patients with advanced solid tumors received intravenous cetrelimab 80, 240, 460, or 800 mg every 2 weeks (Q2W) or 480 mg Q4W. In phase 2, patients with melanoma, non-small-cell lung cancer (NSCLC), and microsatellite instability-high (MSI-H)/DNA mismatch repair-deficient colorectal cancer (CRC) received cetrelimab 240 mg Q2W. Response was assessed Q8W until Week 24 and Q12W thereafter.
Results: In phase 1, 58 patients received cetrelimab. Two dose-limiting toxicities were reported and two recommended phase 2 doses (RP2D) were defined (240 mg Q2W or 480 mg Q4W). After a first dose, mean maximum serum concentrations (C) ranged from 24.7 to 227.0 µg/mL; median time to C ranged from 2.0 to 3.2 h. Pharmacodynamic effect was maintained throughout the dosing period across doses. In phase 2, 146 patients received cetrelimab 240 mg Q2W. Grade ≥ 3 adverse events (AEs) occurred in 53.9% of patients. Immune-related AEs (any grade) occurred in 35.3% of patients (grade ≥ 3 in 6.9%). Overall response rate was 18.6% across tumor types, 34.3% in NSCLC, 52.6% in programmed death ligand 1-high (≥ 50% by immunohistochemistry) NSCLC, 28.0% in melanoma, and 23.8% in centrally confirmed MSI-H CRC.
Conclusions: The RP2D for cetrelimab was established. Pharmacokinetic/pharmacodynamic characteristics, safety profile, and clinical activity of cetrelimab in immune-sensitive advanced cancers were consistent with known PD-1 inhibitors.
Trial Registrations: NCT02908906 at ClinicalTrials.gov, September 21, 2016; EudraCT 2016-002,017-22 at clinicaltrialsregister.eu, Jan 11, 2017.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956549 | PMC |
| http://dx.doi.org/10.1007/s00280-022-04414-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Manifestations of Head and Neck Cancer in Patients With Plummer-Vinson Syndrome: A Systematic Review.
Oral Dis
January 2025
Department of Stomatologic Sciences, School of Dentistry, Federal University of Goiás, Goiânia, Goiás, Brazil.
Objective: To investigate the clinical manifestations of head and neck cancer in patients with Plummer-Vinson syndrome (PVS) and to assess related oral comorbidities.
Materials And Methods: Case reports covering head and neck cancer manifestations in patients diagnosed with PVS were included Studies were identified through seven main electronic databases (PubMed/MEDLINE, EMBASE, Scopus, Web of Science, CINAHL, LILACS, and LIVIVO), and a search for gray literature was performed using ProQuest Dissertations and Theses and Google Scholar. Independent reviewers applied predefined eligibility criteria in a two-phase selection process.
Very low doses of rituximab in autoimmune hemolytic anemia-an open-label, phase II pilot trial.
Front Med (Lausanne)
December 2024
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Introduction: Although rituximab is approved for several autoimmune diseases, no formal dose finding studies have been conducted. The amount of CD20+ cells differs significantly between autoimmune diseases and B-cell malignancies. Hence, dose requirements of anti-CD20 therapies may differ accordingly.
View Article and Find Full Text PDFPhage therapy for extensively drug resistant infection: case report and evaluation of the distribution of phage and the impact on gut microbiome.
Front Med (Lausanne)
December 2024
National Clinical Research Centre for Infectious Diseases, Shenzhen Third People's Hospital and The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Numerous studies have documented successful instances of bacteriophage therapy in treating infections caused by extensively drug-resistant (XDRAB). However, the safety profile of phage therapy and its effects on the human gut microbiota remain areas of concern. In this study, we collected blood, sputum, and fecal samples from an elderly female patient during two phases of inhaled bacteriophage therapy targeting extensively drug-resistant (XDRAB).
View Article and Find Full Text PDFBackground: Recent studies have focused on evaluating the biomarker value of textural features in radiological images. Our study investigated whether or not a texture analysis of computed tomographic colonography (CTC) images could be a novel biomarker for colorectal cancer (CRC).
Methods: This retrospective study investigated 263 patients with CRC who underwent contrast-enhanced CTC (CE-CTC) before curative surgery between January 2014 and December 2017.
Short-term outcomes of robot-assisted versus conventional minimally invasive esophagectomy: A propensity score-matched study via a nationwide database.
Ann Gastroenterol Surg
January 2025
The Japan Society for Endoscopic Surgery Tokyo Japan.
Background: The advantages of robot-assisted minimally invasive esophagectomy (RA-MIE) over conventional minimally invasive esophagectomy (C-MIE) are unknown. This nationwide large-scale study aimed to compare surgical outcomes between RA-MIE and C-MIE using rigorous propensity score methods, including detailed covariates and relevant outcomes.
Methods: This Japanese nationwide retrospective cohort study included RA-MIE or C-MIE for esophageal malignant tumors performed between October 2018 and December 2019 and registered in the Japanese National Clinical Database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!